International Journal of Clinical Pharmacy

, Volume 33, Issue 4, pp 597–598 | Cite as

Practical implications for the administration of 13-cis retinoic acid in pediatric oncology

  • Tiene G. M. BautersEmail author
  • Geneviève Laureys
  • Véronique Van de Velde
  • Yves Benoit
  • Hugo Robays


Children with high-risk neuroblastoma are treated with polychemotherapy, surgery, radiotherapy and even autologous stem-cell transplantation. On top of this complex treatment, most children also receive 13-cis retinoic acid as differentiation agent. As no suitable pharmaceutical formulation is available so far, there are often problems with the administration of the product in children. The present report describes some practical recommendations for the administration of isotretinoin in children treated for high-risk neuroblastoma.


13-cis retinoic acid Clinical pharmacy Pediatric oncology 




Conflicts of interest



  1. 1.
    Maris JM. Recent advances in neuroblastoma. N Engl J Med. 2010;362(23):2202–11.PubMedCrossRefGoogle Scholar
  2. 2.
    Armstrong JL, Redfern CP, Veal GJ. 13-cis retinoic acid and isomerisation in paediatric oncology—is changing shape the key to success? Biochem Pharmacol. 2005;69(9):1299–306.PubMedCrossRefGoogle Scholar
  3. 3.
    E-Compendium. Scientific Leaflet Roaccutane (in Flemish). Available from URL: http:/ Accessed 4 Oct 2010.
  4. 4.
    Matthay K, Reynolds C, Seeger R, Shimada H, Stanton Adkins E, et al. Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: a Children’s Oncology Group Study. J Clin Oncol. 2009;27(7):1007–13.PubMedCrossRefGoogle Scholar
  5. 5.
    Veal GJ, Cole M, Errington J, Pearson A, Foot A, Whyman G, Boddy A. Pharmacokinetics and metabolism of 13-cis-retinoic acid (isotretinoin) in children with high-risk neuroblastoma—a study of the United Kingdom Children’s Cancer Study Group. Br J Cancer. 2007;96(3):424–31.PubMedCrossRefGoogle Scholar
  6. 6.
    Wagner LM, Danks MK. New therapeutic targets for the treatment of high-risk neuroblastoma. J Cell Biochem. 2009;107(1):46–57.PubMedCrossRefGoogle Scholar
  7. 7.
    European Medicines Agency. List of paediatric needs oncology I. Available from URL: Accessed 18 Dec 2010.
  8. 8.
    Priority List of Needs in Pediatric Therapeutics for 2008–2009. National institutes of child health and human development. Available from URL: Accessed 18 Dec 2010.
  9. 9.
    Colburn WA, Gibson DM, Wiens RE, Hanigan JJ. Food increases the bioavailability of isotretinoin. J Clin Pharmacol. 1983;23(11–12):534–9.PubMedGoogle Scholar
  10. 10.
    Barnes CJ, Eichenfield LF, Lee J, Cunningham BB. A practical approach for the use of oral isotretinoin for infantile acne. Pediatr Dermatol. 2005;22(2):166–9.PubMedCrossRefGoogle Scholar
  11. 11.
    Schmidt LE, Dalhoff K. Food-drug interactions. Drugs. 2002;62(10):1481–502.PubMedCrossRefGoogle Scholar
  12. 12.
    Ganceviciene R, Zouboulis CC. Isotretinoin: state of the art treatment for acne vulgaris. J Dtsch Dermatol Ges. 2010;8(S1):S47–59.PubMedGoogle Scholar
  13. 13.
    Lin HS, Leong WW, Yang JA, Lee P, Chan SY, Ho PC. Biopharmaceutics of 13-cis-retinoic acid (isotretinoin) formulated with modified beta-cyclodextrins. Int J Pharm. 2007;341(1–2):238–45.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media B.V. 2011

Authors and Affiliations

  • Tiene G. M. Bauters
    • 1
    Email author
  • Geneviève Laureys
    • 1
  • Véronique Van de Velde
    • 1
  • Yves Benoit
    • 1
  • Hugo Robays
    • 1
  1. 1.Department of Pediatric Hemato-OncologyGhent University HospitalGhentBelgium

Personalised recommendations